Keywords:
Neoplasia, Cirrhosis, Chemoembolisation, Ablation procedures, Ultrasound, Percutaneous, Catheter arteriography, Liver, Interventional vascular, Interventional non-vascular
Authors:
B. Horwitz, P. Vargas, J. P. Niedmann, G. P. Zamboni, D. Hasson, A. Vicentela; Santiago de Chile/CL
DOI:
10.26044/ecr2019/C-2010
Methods and materials
Retrospective descriptive study of patients treated with trans-arterial chemoembolization (TACE) and/or percutaneous ablation of HCC from January 2015 to June 2018.
Inclusion criteria
- Patients who were treated with TACE and/or percutaneous ablation in Clinica Alemana in Santiago,
Chile,
between January 2015 and June 2018.
- BCLC stage (Barcelona Clinic Liver Cancer Staging System) A or B.
- Liver focal lesions classified as LIRADS (Liver Imaging Reporting and Data System) 4 or 5.
Exclusion criteria
- Patients with missing data in the clinical history
- Patients without follow-up with diagnostic images available
Data were retrieved from clinical records and the diagnostic imaging database of our center.
Data were collected in an Excel file.
Patient demographics,
treatment characteristics,
RECIST response rates,
complication rates and preprocedure and post-procedure imaging intervals were analyzed.